Author:
Castro-Ayarza Juan Raúl,Barbosa-Rengifo Mario,Franco-Franco Manuel,Amador Julio Roberto,Cárdenas-Rojas Paola,Becerra-Arias Carolina,Donado-Gómez Jorge,Duque-Zapata Natalia
Reference20 articles.
1. Systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis;Bilal;J Dermatolog Treat,2018
2. Psoriasis in the US Medicare population: prevalence, treatment, and factors associated with biologic use;Takeshita;J Invest Dermatol,2015
3. Use of biologics for psoriasis in Central and Eastern European countries;Rencz;J Eur Acad Dermatol Venereol,2015
4. Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis;Armstrong;JAMA Dermatol,2020
5. Intermittent use of biologic agents for the treatment of psoriasis in adults;Al-Hammadi;J Eur Acad Dermatol Venereol,2021